NO970030L - Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 - Google Patents

Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2

Info

Publication number
NO970030L
NO970030L NO970030A NO970030A NO970030L NO 970030 L NO970030 L NO 970030L NO 970030 A NO970030 A NO 970030A NO 970030 A NO970030 A NO 970030A NO 970030 L NO970030 L NO 970030L
Authority
NO
Norway
Prior art keywords
hla
nucleic acid
tumor rejection
acid sequence
sequence encoding
Prior art date
Application number
NO970030A
Other languages
English (en)
Other versions
NO970030D0 (no
Inventor
Vincent Brichard
Aline Van Pel
Pierre Coulie
Thierry Boon-Falleur
Etienne De Plaen
Catia Traversari
Thomas Wolfel
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO970030D0 publication Critical patent/NO970030D0/no
Publication of NO970030L publication Critical patent/NO970030L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse beskriver nukleinsyremole- kyler som koder for en antigenrejeksjonsforløper. Nærmere bestemt beskrives at tumorrejeksjonsantigenforløperen, eller "TRAP"en, bearbeides til minst ett tumorrejeksjons- antigen som presenteres av HLA-A2-molekyler. Konsekvenser av oppfinnelsen er også angitt.
NO970030A 1994-07-08 1997-01-06 Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 NO970030L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27235194A 1994-07-08 1994-07-08
US08/370,319 US5856091A (en) 1993-03-18 1995-01-10 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1995/008153 WO1996001557A1 (en) 1994-07-08 1995-06-27 Isolated nucleic acid sequence coding for a tumor rejection antigen presented by hla-a2

Publications (2)

Publication Number Publication Date
NO970030D0 NO970030D0 (no) 1997-01-06
NO970030L true NO970030L (no) 1997-01-06

Family

ID=26955454

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970030A NO970030L (no) 1994-07-08 1997-01-06 Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2

Country Status (10)

Country Link
US (2) US5856091A (no)
EP (1) EP0772626A4 (no)
JP (1) JPH10503928A (no)
CN (1) CN1152251A (no)
AU (1) AU696738B2 (no)
CA (1) CA2194451A1 (no)
FI (1) FI970071A0 (no)
NO (1) NO970030L (no)
NZ (1) NZ289616A (no)
WO (1) WO1996001557A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
JPH10505481A (ja) 1994-04-22 1998-06-02 アメリカ合衆国 メラノーマ抗原
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
NZ333149A (en) * 1996-06-25 2000-06-23 Ludwig Inst Cancer Res Brain glycogen phosphorylase tumour rejection antigen precursors including antibodies to and nucleic acids coding them also methods and products for diagnosing and treating conditions characterised by expression of a BGPTR antigen or precursor thereof
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
EP3511425A1 (en) * 2012-07-12 2019-07-17 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
WO2016010975A2 (en) * 2014-07-15 2016-01-21 Illumina, Inc. Biochemically activated electronic device
US10987045B2 (en) 2015-09-14 2021-04-27 Biosense Webster (Israel) Ltd. Basket catheter with individual spine control

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297893A (en) 1963-09-19 1967-01-10 Litz Co Brush mechanisms
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
EP0772626A1 (en) 1997-05-14
FI970071A (fi) 1997-01-07
FI970071A0 (fi) 1997-01-07
US6201111B1 (en) 2001-03-13
NO970030D0 (no) 1997-01-06
NZ289616A (en) 1997-12-19
EP0772626A4 (en) 1997-09-10
WO1996001557A1 (en) 1996-01-25
AU2951795A (en) 1996-02-09
CN1152251A (zh) 1997-06-18
CA2194451A1 (en) 1996-01-25
US5856091A (en) 1999-01-05
JPH10503928A (ja) 1998-04-14
AU696738B2 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
NO953601L (no) Nukleinsyre som koder for en tumorreksjonsantigenforlöper
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
MX9204661A (es) Compuestos intermedios derivados de eter y procedimiento para su preparacion.
ES2098127T3 (es) Procedimiento para la purificacion de taxoides.
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
TR200002921T2 (tr) Yarı-Sentetik ekteinasidinler
IT8023225A0 (it) Processo per la separazione di ammoniaca da gas contenenti ammoniaca.
IT8123284A0 (it) Gas.procedimento per la produzione di
DK0804467T3 (da) Isolerede, trunkerede nukleinsyremolekyler, som koder for GAGE-tumorafstødningsantigen
ATE180489T1 (de) Für leberzellkarzinom spezifisches onkogen
DK0614366T3 (da) Anvendelse af creatinphosphat eller phosphoenolpyrodruesyre til behandling af tumorer
IT8124602A0 (it) Processo per la preparazione di 1,1-dialo-1,2,2,2-etrafluoroetani.
IT8820117A0 (it) Procedimento per la preparazione di bis(2,2,6,6_tetrametil_4_piperidil)ammina.
DE3767493D1 (de) Wanderschichtreaktor zur entfernung von unerwuenschten, gasfoermigen bestandteilen aus gasen.
NO20001404D0 (no) Nye stereoselektive fremgangsmåter for fremstilling av gabapentinanaloger
DK0865278T3 (da) Anvendelse af 1-hydroxy-2-pyridoner til behandling af slimhinde-sygdomme, som er vanskeligt at behandle
IT8520740A0 (it) Procedimento per la concentrazione di virus da fluidi.
IT8221219A0 (it) Procedimento per la produzione di alfa-aminoderivati ciclici di 1(3',4'-metilendiossifenil)etanolo .
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
DK438883D0 (da) 1,2,3,4-tetrahydro-1-aminomethyl-4-phenyl-isoquinoliner, samt fremgangsmade til fremstilling heraf
ES8800203A1 (es) Un procedimiento para la preparacion de piridazinilimidazolidinonas
IT8025322A0 (it) Procedimento per la realizzazione di calzature, nonche' calzatura realizzata.
EP0048532A3 (en) Sultines; a process for producing these; a process for producing sulfoxides; a process for producing sparsomycin and related compounds
SE8500471D0 (sv) Forfarande for uppbyggandet av schaktanleggning for hiss
ATE23336T1 (de) Verfahren zur herstellung von 3,6bis(carbo|thoxyamino)-2,5-diaziridinyl-1,4benzochinon.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application